A resolution expressing the sense of the Senate that the Food and Drug Administration should encourage the use of abuse-deterrent formulations of drugs.
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in senate (Apr 15, 2013)
Expresses the sense of the Senate that the Food and Drug Administration (FDA) should exercise its acknowledged authority to: (1) refuse to approve generic versions of non-abuse-deterrent opioid products that have been replaced in the market with abuse-deterrent formulations recognized by FDA as effective, and (2) require generic versions of abuse-deterrent opioid products to be formulated with comparable abuse-deterrent features.
What just happenedApr 15, 2013
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
Who’s behind it
- Introduced in SenateApr 15, 2013
- Apr 15, 2013IntroReferral
Referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S2654)
- Apr 15, 2013IntroReferral10000
Introduced in Senate